
As debate over COVID-19 origins continues, critics warn that reductions in NIH and CDC biodefense efforts could weaken US pandemic preparedness. From halted CDC databases to shifting NIH priorities, experts question whether scaling back federal response capacity leaves the nation vulnerable to future biological threats and emerging infectious diseases.


























